Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic and Wegovy, were linked to a 33% ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite ...

A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.